Biotech entity
Every one of those 1 sits in a single category, pharma. Scynexis is most often covered alongside Centers for Disease Control and Prevention, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Scynexis, all published on February 27, 2026.
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Scynexis is most often covered alongside Centers for Disease Control and Prevention, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Scynexis, all published on February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Scynexis. Shared-story counts are live from our verified record — not editorial picks.
New York health authorities have issued a high-level alert regarding the accelerated spread of a deadly, drug-resistant fungal pathogen across healthcare facilities. The pathogen, identified as Candida auris, poses a severe threat to immunocompromised patients and highlights a critical gap in the current antifungal pharmaceutical pipeline.
Scynexis is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
